Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $301.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Jazz Pharmaceuticals. According to TipRanks, Amsellem has an average return of 12.9% and a 59.72% success rate on recommended stocks.
In addition to Piper Sandler, Jazz Pharmaceuticals also received a Buy from Truist Financial’s Gregory Renza in a report issued yesterday. However, on June 8, Bernstein reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ).
Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.07 billion and a net profit of $293.1 million. In comparison, last year the company earned a revenue of $897.84 million and had a GAAP net loss of $92.54 million
Based on the recent corporate insider activity of 91 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Earlier this month, Samantha Pearce, the EVP & CCO of JAZZ sold 6,907.00 shares for a total of $1,625,976.87.
Read More on JAZZ:
Disclaimer & DisclosureReport an Issue
- Morning Movers: EchoStar and Rocket Lab lift off ahead of SpaceX IPO
- Jazz Pharmaceuticals says Phase 3 LAGOON trial did not meet primary endpoint
- Jazz Pharmaceuticals price target raised to $307 from $281 at BofA
- Jazz Pharmaceuticals assumed with a Buy at Truist
- Jazz Pharmaceuticals Advances Cannabidiol Trial in Focal-Onset Seizures: What Investors Should Watch
